EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain

Janine Kutzsche, Gustavo A Guzman, Antje Willuweit, Olaf Kletke, Esther Wollert, Ian Gering, Dagmar Jürgens, Jörg Breitkreutz, Holger Stark iD, Annette G Beck-Sickinger, Nikolaj Klöcker, Patricia Hidalgo and 1 more

British Journal of Pharmacology · 2024-06 · 181 (12) · 1734-1756

DOI: 10.1111/bph.16309 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2024-02-07. Written by Janine Kutzsche and 12 co-authors. Institution: Institute of Biological Information Processing 7, Structural Biochemistry, Forschungszentrum Jülich GmbH, Jülich, Germany. Major MEDLINE topics: Calcium Channel Blockers, Calcium Channels, N-Type, Neuralgia. Cited 20 times so far (Crossref); 80 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Forschungszentrum Jülich, Helmholtz Association.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Neuropathic pain affects up to 10% of the global population and is caused by an injury or a disease affecting the somatosensory, peripheral, or central nervous system. NP is characterized by chronic, severe and opioid‐resistant properties. Therefore, its clinical management remains very challenging. The N‐type voltage‐gated calcium channel, Ca v 2.2, is a validated target for therapeutic intervention in chronic and neuropathic pain. The conotoxin ziconotide (Prialt®) is an FDA‐approved drug that blocks Ca v 2.2 channel but needs to be administered intrathecally. Thus, although being principally efficient, the required application route is very much in disfavour. Experimental Approach and Key Results Here, we describe an orally available drug candidate, RD2, which competes with ziconotide binding to Ca v 2.2 at nanomolar concentrations and inhibits Ca v 2.2 almost completely reversible. Other voltage‐gated calcium channel subtypes, like Ca v 1.2 and Ca v 3.2, were affected by RD2 only at concentrations higher than 10 μM. Data from sciatic inflammatory neuritis rat model demonstrated the in vivo proof of concept, as low‐dose RD2 (5 mg·kg ‐1 ) administered orally alleviated neuropathic pain compared with vehicle controls. High‐dose RD2 (50 mg·kg ‐1 ) was necessary to reduce pain sensation in acute thermal response assessed by the tail flick test. Conclusions and Implications Taken together, these results demonstrate that RD2 has antiallodynic properties. RD2 is orally available, which is the most convenient application form for patients and caregivers. The surprising and novel result from standard receptor screens opens the room for further optimization into new promising drug candidates, which address an unmet medical need.

Subjects

MeSH terms (MEDLINE)

Calcium Channel BlockersCalcium Channels, N-TypeNeuralgiaAnimalsHumansMaleMiceRatsAdministration, OralDose-Response Relationship, DrugMice, Inbred C57BLomega-ConotoxinsRats, Inbred Lew

Author keywords

N‐type calcium channelPrialt®SNX 111d‐enantiomeric peptideneuropathic pain treatmentziconotideω‐Conotoxin MVIIA

Substances

CACNA1B protein, humanCalcium Channel BlockersCalcium Channels, N-Typeomega-Conotoxinsziconotide

Authors and institutions

  • Institute of Biological Information Processing 7, Structural Biochemistry, Forschungszentrum Jülich GmbH, Jülich, Germany.
  • Institute of Neuroscience and Medicine, Medical Imaging Physics, Forschungszentrum Jülich GmbH, Jülich, Germany.
  • Institute of Neuro- und Sensory Physiology, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
  • Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
  • Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Institute of Biochemistry, Universität Leipzig, Leipzig, Germany.

ORCID profiles: Holger Stark

Funding

  • Forschungszentrum Jülich
  • Helmholtz Association

Cite

APA

Kutzsche, J., Guzman, G. A., Willuweit, A., Kletke, O., Wollert, E., Gering, I., Jürgens, D., Breitkreutz, J., Stark, H., Beck-Sickinger, A. G., Klöcker, N., Hidalgo, P., & Willbold, D. (2024). An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain. British Journal of Pharmacology, 181(12), 1734-1756. https://doi.org/10.1111/bph.16309

Vancouver

Kutzsche J, Guzman GA, Willuweit A, Kletke O, Wollert E, Gering I, et al. An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain. British Journal of Pharmacology. 2024;181(12):1734-1756. doi:10.1111/bph.16309

BibTeX
@article{Kutzsche2024,
  author = {Kutzsche, Janine and Guzman, Gustavo A and Willuweit, Antje and Kletke, Olaf and Wollert, Esther and Gering, Ian and Jürgens, Dagmar and Breitkreutz, Jörg and Stark, Holger and Beck-Sickinger, Annette G and Klöcker, Nikolaj and Hidalgo, Patricia and Willbold, Dieter},
  title = {An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {12},
  pages = {1734--1756},
  doi = {10.1111/bph.16309}
}
Start for free →